FierceBiotech Radio on Teva vs. Mylan, 'female Viagra' and the next cardio blockbusters

FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the week's biggest news in biopharma, including the ongoing squabble between Teva and Mylan, the debate over a new class of cholesterol treatments, and the regulatory saga of a long-delayed female libido drug.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.